{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:44:29Z","timestamp":1789782269120,"version":"4.0.1"},"reference-count":79,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000071","name":"Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development, Bethesda","doi-asserted-by":"publisher","award":["U54HD071594"],"award-info":[{"award-number":["U54HD071594"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Bevacizumab (Avastin) is a vascular endothelial growth factor (VEGF) inhibitor that is widely used for aggressive posterior retinopathy of prematurity (APROP). Its use is associated with multiple adverse effects. Aflibercept (Eylea) is a VEGFR-1 analogue that is approved for ocular use, but its efficacy for APROP is less studied. We tested the hypothesis that Eylea is as effective as Avastin for suppression of intermittent hypoxia (IH)-induced angiogenesis. Human retinal microvascular endothelial cells (HRECs) were treated with Avastin and low- or high-dose Eylea and exposed to normoxia, hyperoxia (50% O2), or neonatal IH for 24, 48, or 72 h. Cells were assessed for migration and tube formation capacities, as well as biomarkers of angiogenesis and oxidative stress. Both doses of Eylea suppressed migration and tube formation in all oxygen environments, although the effect was not as robust as Avastin. Furthermore, the lower dose of Eylea appeared to be more effective than the higher dose. Eylea induced soluble VEGFR-1 (sVEGFR-1) coincident with high IGF-I levels and decreased Notch\/Jagged-1, demonstrating a functional association. Given the role of VEGFR-1 and Notch as guidance cues for vascular sprouting, these data suggest that Eylea may promote normal vascular patterning in a dose-dependent manner.<\/jats:p>","DOI":"10.3390\/ph16070939","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T01:53:57Z","timestamp":1688003637000},"page":"939","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of Bevacizumab and Aflibercept for Suppression of Angiogenesis in Human Retinal Microvascular Endothelial Cells"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5393-5243","authenticated-orcid":false,"given":"Amirfarbod","family":"Yazdanyar","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA"},{"name":"Retina Group of New England, Waterford, CT 06385, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob V.","family":"Aranda","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA"},{"name":"Department of Pediatrics\/Division of Neonatal-Perinatal Medicine, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Shrier","sequence":"additional","affiliation":[{"name":"Department of Pediatrics\/Division of Neonatal-Perinatal Medicine, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4129-475X","authenticated-orcid":false,"given":"Kay D.","family":"Beharry","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA"},{"name":"Department of Pediatrics\/Division of Neonatal-Perinatal Medicine, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"C1358","DOI":"10.1152\/ajpcell.2001.280.6.C1358","article-title":"Role of vascular endothelial growth factor in regulation of physiological angiogenesis","volume":"280","author":"Ferrara","year":"2001","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0958-1669(00)00153-1","article-title":"VEGF: An update on biological and therapeutic aspects","volume":"11","author":"Ferrara","year":"2000","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1042\/CS20040370","article-title":"The vascular endothelial growth factor (VEGF)\/VEGF receptor system and its role under physiological and pathological conditions","volume":"109","author":"Takahashi","year":"2005","journal-title":"Clin. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling\u2014In control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","article-title":"Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor","volume":"92","author":"Soker","year":"1998","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm0603-677","article-title":"Regulation of angiogenesis by hypoxia: Role of the HIF system","volume":"9","author":"Pugh","year":"2003","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1242\/jcs.114.5.853","article-title":"The splice variants of vascular endothelial growth factor (VEGF) and their receptors","volume":"114","author":"Robinson","year":"2001","journal-title":"J. Cell Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"627674","DOI":"10.1155\/2015\/627674","article-title":"Anti-VEGF Therapy and the Retina: An Update","volume":"2015","author":"Tah","year":"2015","journal-title":"J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0301-4738.29505","article-title":"Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity","volume":"55","author":"Shah","year":"2007","journal-title":"Indian J. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Kennedy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.semperi.2015.12.006","article-title":"Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity","volume":"40","author":"Beharry","year":"2016","journal-title":"Semin. Perinatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaapos.2013.12.009","article-title":"Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy","volume":"18","year":"2014","journal-title":"J. AAPOS"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaapos.2013.01.004","article-title":"Exudative retinopathy and detachment: A late reactivation of retinopathy of prematurity after intravitreal bevacizumab","volume":"17","author":"Ittiara","year":"2013","journal-title":"J. AAPOS"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"F327","DOI":"10.1136\/archdischild-2012-302365","article-title":"Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5","volume":"98","author":"Jalali","year":"2012","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaophthalmol.2013.400","article-title":"Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity","volume":"131","author":"Karaca","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"Schwartz","year":"2013","journal-title":"Retina"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/08820538.2013.835842","article-title":"Unusual Adverse Choroidal Reaction to Intravitreal Bevacizumab in Aggressive Posterior Retinopathy of Prematurity: The Indian Twin Cities ROP Screening (ITCROPS) Data Base Report Number 7","volume":"29","author":"Chablani","year":"2014","journal-title":"Semin. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"Tahija","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/IAE.0000000000000535","article-title":"Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection","volume":"35","author":"Hong","year":"2015","journal-title":"Retina"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/bjo.2007.128371","article-title":"VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: Relationship to retinopathy of prematurity","volume":"92","author":"Pieh","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators. Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"(2008). Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap\u2013Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye. Drugs R&D, 9, 261\u2013269.","DOI":"10.2165\/00126839-200809040-00006"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1517\/13543780903201684","article-title":"VEGF trap-eye for the treatment of neovascular age-related macular degeneration","volume":"18","author":"Dixon","year":"2009","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5301\/ejo.5000938","article-title":"Effect of Intravitreal Aflibercept on Central Retinal Arterial Blood Flow in Type 1 Retinopathy of Prematurity","volume":"27","author":"Sukgen","year":"2017","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity","volume":"53","author":"Salman","year":"2015","journal-title":"Ophthalmic Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":"Effects and complications of bevacizumab use in patients with retinopathy of prematurity: A multicenter study in Taiwan","volume":"118","author":"Wu","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaapos.2010.05.011","article-title":"Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity","volume":"14","author":"Jang","year":"2010","journal-title":"J. AAPOS"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3928\/01913913-20101217-06","article-title":"Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity","volume":"47","author":"Suk","year":"2010","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","article-title":"Retinopathy of prematurity","volume":"10","author":"Chen","year":"2007","journal-title":"Angiogenesis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clp.2019.05.006","article-title":"Intermittent Hypoxemia in Preterm Infants","volume":"46","author":"MacFarlane","year":"2019","journal-title":"Clin. Perinatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jpeds.2010.01.046","article-title":"A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity","volume":"157","author":"Bloom","year":"2010","journal-title":"J. Pediatr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.resp.2019.05.006","article-title":"Intermittent hypoxemia and oxidative stress in preterm infants","volume":"266","author":"Vento","year":"2019","journal-title":"Respir. Physiol. Neurobiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1542\/peds.107.4.642","article-title":"Resuscitation with room air instead of 100% oxygen prevents oxidative stress in moderately asphyxiated term neonates","volume":"107","author":"Vento","year":"2001","journal-title":"Pediatrics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4353129","DOI":"10.1155\/2017\/4353129","article-title":"Ocular Adverse Effects of Intravitreal Bevacizumab Are Potentiated by Intermittent Hypoxia in a Rat Model of Oxygen-Induced Retinopathy","volume":"2017","author":"Tan","year":"2017","journal-title":"J. Ophthalmol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/01902148.2017.1306897","article-title":"Intravitreal bevacizumab alters type IV collagenases and exacerbates arrested alveologenesis in the neonatal rat lungs","volume":"43","author":"Valencia","year":"2017","journal-title":"Exp. Lung Res."},{"key":"ref_40","first-page":"121","article-title":"Acute and chronic effects of intravitreal bevacizumab on lung biomarkers of angiogenesis in the rat exposed to neonatal intermittent hypoxia","volume":"47","author":"Duggan","year":"2021","journal-title":"Exp. Lung Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/labinvest.3780050","article-title":"Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids","volume":"80","author":"Hornig","year":"2000","journal-title":"Lab. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1182\/blood-2003-07-2315","article-title":"The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis","volume":"103","author":"Kearney","year":"2004","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.devcel.2009.07.011","article-title":"Local guidance of emerging vessel sprouts requires soluble Flt-1","volume":"17","author":"Chappell","year":"2009","journal-title":"Dev. Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/08977194.2013.802692","article-title":"Associations between insulin-like growth factor I, vascular endothelial growth factor and its soluble receptor 1 in umbilical serum and endothelial cells obtained from normotensive and preeclamptic pregnancies","volume":"31","author":"Olmos","year":"2013","journal-title":"Growth Factors"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jtbi.2018.08.005","article-title":"Soluble VEGFR1 signaling guides vascular patterns into dense branching morphologies","volume":"456","author":"Lakatos","year":"2018","journal-title":"J. Theor. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.exer.2006.01.016","article-title":"Oxygen-dependent diseases in the retina: Role of hypoxia inducible factors","volume":"83","author":"Arjamaa","year":"2006","journal-title":"Exp. Eye Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/archopht.121.4.547","article-title":"Retinal oxygen: Fundamental and clinical aspects","volume":"121","author":"Linsenmeier","year":"2003","journal-title":"Arch. Ophthalmol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10633-009-9197-2","article-title":"Oxygen supply and consumption in the retina: Implications for studies of retinopathy of prematurity","volume":"120","author":"Cringle","year":"2010","journal-title":"Doc. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10456-016-9515-8","article-title":"Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes","volume":"19","author":"MacDonald","year":"2016","journal-title":"Angiogenesis"},{"key":"ref_50","first-page":"1055","article-title":"Cell proliferation and migration in glioblastoma multiforme cell lines are influenced by insulin-like growth factor I in vitro","volume":"28","author":"Lange","year":"2008","journal-title":"Anticancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/bjo.78.8.638","article-title":"Production of IGF-I and IGF binding proteins by retinal cells in vitro","volume":"78","author":"Moriarty","year":"1994","journal-title":"Br. J. Ophthalmol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.febslet.2013.05.038","article-title":"VEGF-A induces its negative regulator, soluble form of VEGFR-1, by modulating its alternative splicing","volume":"587","author":"Saito","year":"2013","journal-title":"FEBS Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0002-9440(10)63711-X","article-title":"The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation","volume":"164","author":"Roberts","year":"2004","journal-title":"Am. J. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1083\/jcb.200709114","article-title":"The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching","volume":"181","author":"Kappas","year":"2008","journal-title":"J. Cell Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1161\/ATVBAHA.113.301805","article-title":"Flt-1 (vascular endothelial growth factor receptor-1) is essential for the vascular endothelial growth factor-Notch feedback loop during angiogenesis","volume":"33","author":"Chappell","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ymthe.2003.10.003","article-title":"Insulin-like growth factor I plasmid therapy promotes in vivo angiogenesis","volume":"9","author":"Rabinovsky","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"21695","DOI":"10.1074\/jbc.M000805200","article-title":"Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways","volume":"275","author":"Miele","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s10815-019-01618-3","article-title":"Insulin-like growth factor-1 and soluble FMS-like tyrosine kinase-1 prospectively predict cancelled IVF cycles","volume":"36","author":"Nasioudis","year":"2019","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/ncb2103","article-title":"Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting","volume":"12","author":"Jakobsson","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1369\/0022155412467635","article-title":"Endothelial tip cells in ocular angiogenesis: Potential target for anti-angiogenesis therapy","volume":"61","author":"Siemerink","year":"2013","journal-title":"J. Histochem. Cytochem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1083\/jcb.200302047","article-title":"VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia","volume":"161","author":"Gerhardt","year":"2003","journal-title":"J. Cell Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","article-title":"Basic and therapeutic aspects of angiogenesis","volume":"146","author":"Potente","year":"2011","journal-title":"Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.devcel.2009.01.015","article-title":"Angiogenesis: A team effort coordinated by notch","volume":"16","author":"Phng","year":"2009","journal-title":"Dev. Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.cell.2009.03.025","article-title":"The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis","volume":"137","author":"Benedito","year":"2009","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature05571","article-title":"Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis","volume":"445","author":"Hellstrom","year":"2007","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.1167\/iovs.13-13040","article-title":"Hydrogen Peroxide Accumulation in the Choroid During Intermittent Hypoxia Increases Risk of Severe Oxygen-Induced Retinopathy in Neonatal Rats","volume":"54","author":"Beharry","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_67","first-page":"2063","article-title":"The range of PaO2 variation determines the severity of oxygen-induced retinopathy in newborn rats","volume":"36","author":"Penn","year":"1995","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-94-007-4584-1_47","article-title":"Physiologic basis for intermittent hypoxic episodes in preterm infants","volume":"758","author":"Martin","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000329922","article-title":"Intermittent hypoxic episodes in preterm infants: Do they matter?","volume":"100","author":"Martin","year":"2011","journal-title":"Neonatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/adc.66.4_Spec_No.381","article-title":"Apnoea, bradycardia, and oxygen saturation in preterm infants","volume":"66","author":"Upton","year":"1991","journal-title":"Arch. Dis. Child."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"721043","DOI":"10.1155\/2014\/721043","article-title":"Antioxidant strategies and respiratory disease of the preterm newborn: An update","volume":"2014","author":"Poggi","year":"2014","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1055\/s-0035-1544948","article-title":"Antioxidants and Biomarkers of Oxidative Stress in Preterm Infants with Symptomatic Patent Ductus Arteriosus","volume":"32","author":"Inayat","year":"2015","journal-title":"Am. J. Perinatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.siny.2010.04.001","article-title":"Maturation of the antioxidant system and the effects on preterm birth","volume":"15","author":"Davis","year":"2010","journal-title":"Semin. Fetal Neonatal Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1523\/JNEUROSCI.12-03-00840.1992","article-title":"Energy metabolism of rabbit retina as related to function: High cost of Na+ transport","volume":"12","author":"Ames","year":"1992","journal-title":"J. Neurosci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1001\/archopht.1964.00970020794009","article-title":"Retinal oxygen utilization measured by hyperbaric blackout","volume":"72","author":"Anderson","year":"1964","journal-title":"Arch. Ophthalmol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1350-9462(00)00027-6","article-title":"Oxygen distribution and consumption within the retina in vascularised and avascular retinas and in animal models of retinal disease","volume":"20","author":"Yu","year":"2001","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4049\/jimmunol.181.1.346","article-title":"Oxidative stress regulates expression of VEGFR1 in myeloid cells: Link to tumor-induced immune suppression in renal cell carcinoma","volume":"181","author":"Kusmartsev","year":"2008","journal-title":"J. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/ajh.2009.24","article-title":"Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats","volume":"22","author":"Bridges","year":"2009","journal-title":"Am. J. Hypertens."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4103\/0301-4738.124750","article-title":"Effect of bevacizumab (Avastin (TM) on mitochondrial function of in vitro retinal pigment epithelial, neurosensory retinal and microvascular endothelial cells","volume":"61","author":"Luthra","year":"2013","journal-title":"Indian J. Ophthalmol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/7\/939\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:03:14Z","timestamp":1760126594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/7\/939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":79,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ph16070939"],"URL":"https:\/\/doi.org\/10.3390\/ph16070939","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}